secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0000010795-25-000036
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD Q2 fiscal 2025: Revenue $5.27B (+4.5%), GAAP EPS $1.07 (down 42% YoY), adj. EPS $3.35
--------------------------------------------------------------------------------

- Revenue increased 4.5% as reported to $5.272B; organic growth 0.9%, currency-neutral growth 6.0%.
- GAAP diluted EPS $1.07, down 42.2% YoY; adjusted diluted EPS $3.35, up 5.7% YoY.
- Company updates full-year fiscal 2025 guidance and provides estimated tariff impact; specific numbers not detailed.
- Announces intention to invest $2.5B in U.S. manufacturing capacity over next 5 years.
- Business highlights include FDA clearances for Phasix ST Umbilical Hernia Patch and advanced microbiology solution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000001079525000036/0000010795-25-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000001079525000036/bdx-20250501.htm
  HTML page:      https://secwatch.observer/filing/0000010795-25-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer